Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of the Company’s intimation dated November 29, 2025, wherein it was informed that the Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, had appointed Dr. Yogananda Moolemath (DIN: 02870387) as an Independent Director with effect from January 01, 2026, Pharmaids Pharmaceuticals has informed that the said appointment has been approved by the shareholders through a postal ballot, the results of which were declared on January 02, 2026. The disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with SEBI Master Circular in respect of aforesaid appointment is enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.65 |
| Dr. Reddys Lab | 1222.20 |
| Cipla | 1232.45 |
| Zydus Lifesciences | 928.45 |
| Lupin | 2322.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: